Cited by 123Protein Degradation and InhibitorsUbiquitin and proteasome pathwaysCRISPR and Genetic Engineering

Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins

Open access
Shirasaki, Ryosuke, Matthews, Geoffrey M., Gandolfi, Sara, de Matos Simoes, Ricardo, Buckley, Dennis L., Raja Vora, Joseline, Sievers, Quinlan L., Brüggenthies, Johanna B. +31 more·2021·Cell Reports

Abstract

Heterobifunctional proteolysis-targeting chimeric compounds leverage the activity of E3 ligases to induce degradation of target oncoproteins and exhibit potent preclinical antitumor activity. To dissect the mechanisms regulating tumor cell sensitivity to different classes of pharmacological "degraders" of oncoproteins, we performed genome-scale CRISPR-Cas9-based gene editing studies. We observed that myeloma cell resistance to degraders of different targets (BET bromodomain proteins, CDK9) and operating through CRBN (degronimids) or VHL is primarily mediated by prevention of, rather than adaptation to, breakdown of the target oncoprotein; and this involves loss of function of the cognate E3 ligase or interactors/regulators of the respective cullin-RING ligase (CRL) complex. The substantial gene-level differences for resistance mechanisms to CRBN- versus VHL-based degraders explains mechanistically the lack of cross-resistance with sequential administration of these two degrader classes. Development of degraders leveraging more diverse E3 ligases/CRLs may facilitate sequential/alternating versus combined uses of these agents toward potentially delaying or preventing resistance.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2020.108532

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Most emerging mutations occur directly in the SR of the involved E3 ligase.

    “In line with previous studies that employed CRISPR/Cas9 screens13–15, we show that most emerging mutations occur directly in the SR of the involved E3 ligase.”
  • Several functional genomics campaigns have helped map how the repertoire of CRLs and their regulators shape degrader efficacy, outlining putative resistance mechanisms.

    “Several functional genomics campaigns in recent years have helped map how the repertoire of CLRs and their regulators shape degrader efficacy, thus also outlining putative resistance mechanisms.141-151”

    From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [148]

  • PROTACs were shown to be substrates for MDR1.

    “Recently, PROTACs were shown to be substrates for MDR1 (10, 13), suggesting that drug efflux represents a potential limitation for degrader therapies.”
  • Resistance to PROTACs in cultured cells has been shown to involve genomic alterations in their E3 ligase targets, such as decreased expression of CRBN, VHL, or CUL2.

    “Resistance to PROTACs in cultured cells has been shown to involve genomic alterations in their E3 ligase targets, such as decreased expression of Cereblon (CRBN), Von Hippel Lindau (VHL), or Cullin2 (CUL2) (9–11).”
  • Preclinical studies of degraders that use CRBN or VHL to target multiple protein classes have detected emerging resistance via mutation and/or downregulation of components of the ubiquitin ligase machinery.

    “In fact, preclinical studies of degraders that use CRBN or VHL to target multiple protein classes have detected emerging resistance that occurs via mutation and/or downregulation of components of the ubiquitin ligase machinery99–101.”

    From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [99]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 77 · Cited by 123

Authors
Shirasaki, R., Matthews, G. M., Gandolfi, S., de Matos Simoes, R., Buckley, D. L., Raja Vora, J., Sievers, Q. L., Brüggenthies, J. B., Dashevsky, O., Poarch, H., Tang, H., Bariteau, M. A., Sheffer, M., Hu, Y., Downey-Kopyscinski, S. L., Hengeveld, P. J., Glassner, B. J., Dhimolea, E., Ott, C. J., Zhang, T., Kwiatkowski, N. P., Laubach, J. P., Schlossman, R. L., Richardson, P. G., Culhane, A. C., Groen, R. W. J., Fischer, E. S., Vazquez, F., Tsherniak, A., Hahn, W. C., Levy, J., Auclair, D., Licht, J. D., Keats, J. J., Boise, L. H., Ebert, B. L., Bradner, J. E., Gray, N. S., & Mitsiades, C. S.
Affiliations
  • Broad Institute (US)
  • Dana-Farber Cancer Institute (US)
  • Harvard University (US)
  • Amsterdam University Medical Centers (NL)
  • Multiple Myeloma Research Foundation (US)
  • University of Florida Health (US)
  • Translational Genomics Research Institute (US)
  • Emory University (US)
Corresponding author
Mitsiades, Constantine S.
Venue
Cell Reports
Publisher
Elsevier BV
Published
2021-01
Volume
34
Issue
1
Pages
108532
ISSN
2211-1247 (ISSN-L)
OpenAlex
W3119591201
Cited by
123
References
77
Citations by year
2026: 22 · 2025: 20 · 2024: 32 · 2023: 23 · 2022: 18 · 2021: 7
FWCI
6.28
Type
journal article
Language
en
Open access
Locations
  • Cell Reports (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Damon Runyon Cancer Research Foundation (DRG219614)
  • National Institutes of Health (CA196664, U01 CA225730, CA180475, U01CA176058, CA179483, R01 CA050947)
  • National Institute of General Medical Sciences (T32GM007753)
  • American Australian Association
  • Takeda Pharmaceuticals U.S.A.
  • Teva Pharmaceutical Industries
  • Novartis (EcoR1)
  • Dana-Farber Cancer Institute (T32GM007753)
  • Ludwig Center at Harvard
  • U.S. Department of Defense (W81XWH-15-1-0013, W81XWH-15-1-0012)
  • University of Texas MD Anderson Cancer Center
  • Minneapolis Medical Research Foundation
  • Associazione Italiana per la Ricerca sul Cancro
  • International Myeloma Foundation
  • Roche
  • EMD Serono
  • Astellas Pharma US
  • Lauri Strauss Leukemia Foundation
  • AstraZeneca
  • Genentech
  • Leukemia and Lymphoma Society
  • Chambers Family Fund
  • Ionis Pharmaceuticals
  • Multiple Myeloma Research Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Keywords
heterobifunctional degraders, oncoprotein degradation, CRISPR-Cas9 screen, drug resistance mechanisms, BET proteins, CDK9, cereblon, VHL, E3 ubiquitin ligase, cullin-RING ligases, multidrug resistance, multiple myeloma, sequential administration, resistance prevention
MeSH terms
Gene Editing, Bromodomain Containing Proteins, Animals, Antineoplastic Agents, Genes, Overlapping, Humans, Multiple Myeloma, Proteins, Tumor Cells, Cultured, Oncogene Proteins, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Genomics, Cyclin-Dependent Kinase 9, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Mice, Von Hippel-Lindau Tumor Suppressor Protein, Genome-Wide Association Study, Proteolysis, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review